Evidence map›Paper›PMID 38569115›Full record

ArticleJournal of the American Chemical Society2024

Proteomic Ligandability Maps of Spirocycle Acrylamide Stereoprobes Identify Covalent ERCC3 Degraders.

Zhonglin Liu, Jarrett R Remsberg, Haoxin Li, Evert Njomen, Kristen E DeMeester, Yongfeng Tao, Guoqin Xia, Rachel E Hayward, Minjin Yoo, Tracey Nguyen and 4 more

Open access · greenAbstract read
In one paragraph

Article in Journal of the American Chemical Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
9.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Targeting extrachromosomal DNA in human cancers.Nature reviews. Drug discovery · 2026
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Covalent Proximity Inducers.Chemical reviews · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Zhonglin LiuDepartment of Chemistry, Scripps Research, La Jolla, California 92037, United States.
Jarrett R RemsbergDepartment of Chemistry, Scripps Research, La Jolla, California 92037, United States.
Haoxin LiDepartment of Chemistry, Scripps Research, La Jolla, California 92037, United States.
Evert NjomenDepartment of Chemistry, Scripps Research, La Jolla, California 92037, United States.
Kristen E DeMeesterDepartment of Chemistry, Scripps Research, La Jolla, California 92037, United States.
Yongfeng TaoDepartment of Chemistry, Scripps Research, La Jolla, California 92037, United States.ORCID 0000-0001-8884-204X
Guoqin XiaDepartment of Chemistry, Scripps Research, La Jolla, California 92037, United States.
Rachel E HaywardDepartment of Chemistry, Scripps Research, La Jolla, California 92037, United States.ORCID 0000-0002-1080-8244
Minjin YooDepartment of Chemistry, Scripps Research, La Jolla, California 92037, United States.
Tracey NguyenVividion Therapeutics, San Diego, California 92121, United States.
Gabriel M SimonVividion Therapeutics, San Diego, California 92121, United States.
Stuart L SchreiberChemical Biology and Therapeutics Science Program, Broad Institute, Cambridge, Massachusetts 02142, United States.ORCID 0000-0003-1922-7558
Bruno MelilloDepartment of Chemistry, Scripps Research, La Jolla, California 92037, United States.ORCID 0000-0002-9708-5287
Benjamin F CravattDepartment of Chemistry, Scripps Research, La Jolla, California 92037, United States.ORCID 0000-0001-5330-3492
Scripps Institution of Oceanography · USBroad Institute · USVividion Therapeutics (United States) · US

Funding

Chemical Proteomic Platforms for Radically Expanding Cancer DruggabilityR35CA231991 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI BENJAMIN F CRAVATT · 2018 to 2026
$9.5M
eDyNAmiC - STANFORDOT2CA278688 · NCI · STANFORD UNIVERSITY · PI PAUL S MISCHEL · 2022 to 2026
$7.7M
eDyNAmiC - SCRIPPSOT2CA278692 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI BENJAMIN F CRAVATT · 2022 to 2026
$2.1M
Discovering and Characterizing Druggable Cysteines in Cancer Dependency ProteinsK99CA290143 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI LI, HAOXIN · 2024 to 2025
$332k
Cancer Research UK CGCATF-2021/100012NCI NIH HHS K99 CA290143NCI NIH HHS OT2 CA278688NCI NIH HHS OT2 CA278692NCI NIH HHS R35 CA231991
6 · The paper itself

Abstract

Covalent chemistry coupled with activity-based protein profiling (ABPP) offers a versatile way to discover ligands for proteins in native biological systems. Here, we describe a set of stereo- and regiochemically defined spirocycle acrylamides and the analysis of these electrophilic "stereoprobes" in human cancer cells by cysteine-directed ABPP. Despite showing attenuated reactivity compared to structurally related azetidine acrylamide stereoprobes, the spirocycle acrylamides preferentially liganded specific cysteines on diverse protein classes. One compound termed ZL-12A promoted the degradation of the TFIIH helicase ERCC3. Interestingly, ZL-12A reacts with the same cysteine (C342) in ERCC3 as the natural product triptolide, which did not lead to ERCC3 degradation but instead causes collateral loss of RNA polymerases. ZL-12A and triptolide cross-antagonized one another's protein degradation profiles. Finally, we provide evidence that the antihypertension drug spironolactone─previously found to promote ERCC3 degradation through an enigmatic mechanism─also reacts with ERCC3_C342. Our findings thus describe monofunctional degraders of ERCC3 and highlight how covalent ligands targeting the same cysteine can produce strikingly different functional outcomes.

Indexed as

AcrylamideDiterpenesPhenanthrenesCysteineEpoxy CompoundsHumansProteomicsAcrylamideCysteineDiterpenesEpoxy CompoundsPhenanthrenestriptolide

Identifiers

PMID38569115
PMCPMC11211653
OpenAlexW4393852623

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.